Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys
Rhea-AI Filing Summary
Scribe Therapeutics, Inc. Chief Financial Officer David Parrot reported multiple equity awards and open-market purchases. On July 23, 2026 he received stock options for 109,426 shares at $15.00 per share that vest monthly over four years, plus performance-based options for 109,426 shares at $15.00 that may vest between July 23, 2026 and July 23, 2029 based on market-based criteria. He also reported indirect open-market purchases of 1,333 common shares for a spouse and 1,333 shares for a child at $15.00 per share. A prior option grant for 8,909 shares at $19.13, fully vested and expiring March 12, 2036, was also disclosed under Rule 16a-2(a) in connection with the company’s initial public offering.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,666 shares
Net Buy
5 txns
Insider
Parrot David
Role
Chief Financial Officer
Bought
2,666 shs ($40K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F3 | 109,426 | $0.00 | $0.00 |
| Grant/Award | Performance-based Stock Option (Right to Buy) F4 | 109,426 | $0.00 | $0.00 |
| Purchase | Common Stock | 1,333 | $15.00 | $20K |
| Purchase | Common Stock | 1,333 | $15.00 | $20K |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 8,909 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 118,335 shares (Direct);
Performance-based Stock Option (Right to Buy) — 109,426 shares (Direct);
Common Stock — 1,333 shares (Indirect, By Spouse);
Common Stock — 1,333 shares (Indirect, By Child)
Footnotes (4)
- F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
- F2. The option is fully vested.
- F3. The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- F4. The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Key Figures
Time-vested options granted: 109,426 shares at $15.00
Performance-based options granted: 109,426 shares at $15.00
Monthly vesting schedule: 1/48 per month over 4 years
+3 more
6 metrics
Time-vested options granted
109,426 shares at $15.00
Stock Option (Right to Buy) granted July 23, 2026, expiring July 22, 2036
Performance-based options granted
109,426 shares at $15.00
Performance-based Stock Option granted July 23, 2026, expiring July 22, 2036
Monthly vesting schedule
1/48 per month over 4 years
Time-vested options start vesting August 23, 2026, subject to continued service
Performance period
July 23, 2026 to July 23, 2029
Window during which market-based criteria may be achieved for performance options
Family share purchases
2,666 shares at $15.00
1,333 shares for spouse and 1,333 shares for child on July 23, 2026
Prior fully vested options
8,909 shares at $19.13
Option granted March 13, 2026 (pre-IPO), fully vested, expiring March 12, 2036
Key Terms
Performance-based Stock Option, market-based performance criteria, Rule 16a-2(a), initial public offering
4 terms
Performance-based Stock Option financial
"Performance-based Stock Option (Right to Buy) with market-based criteria"
market-based performance criteria financial
"eligible to vest upon the achievement of certain market-based performance criteria"
Rule 16a-2(a) regulatory
"transaction is reported herein pursuant to Rule 16a-2(a)."
initial public offering financial
"in connection with the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
FAQ
What stock option grants did Scribe Therapeutics (SCTX) CFO David Parrot receive?
David Parrot received two option grants on July 23, 2026: 109,426 standard options at $15.00 per share and 109,426 performance-based options at $15.00, both expiring July 22, 2036 and tied to continued service and, for the latter, market-based criteria.
How do the new SCTX CFO options vest for David Parrot?
One option grant for 109,426 shares vests monthly over four years, 1/48 each month, starting August 23, 2026, subject to continued service. The 109,426 performance-based options may vest between July 23, 2026 and July 23, 2029 upon meeting market-based performance criteria.
What is the prior SCTX option grant disclosed under Rule 16a-2(a)?
An earlier grant of 8,909 options at an exercise price of $19.13 per share, fully vested and expiring March 12, 2036, was reported. It occurred before Scribe Therapeutics registered its equity under Section 12, and is disclosed pursuant to Rule 16a-2(a).
Are the SCTX CFO’s July 23, 2026 transactions under a 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the footnotes do not describe any trading plan. The reported July 23, 2026 option grants and common stock purchases are therefore not identified as being made under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
